Tyr988
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr988  -  PDGFRA (human)

Site Information
RVDSDNAyIGVtyKN   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 450905
Available spectra:  1 CST
Associated spectra:  4 CST

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 25 , 26 ) , immunoprecipitation ( 26 ) , mass spectrometry ( 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 ) , mutation of modification site ( 24 , 26 ) , phospho-antibody ( 24 , 25 , 26 ) , phosphoamino acid analysis ( 25 ) , phosphopeptide mapping ( 25 ) , western blotting ( 24 )
Disease tissue studied:
bone cancer ( 6 ) , osteosarcoma ( 6 ) , brain cancer ( 4 , 9 , 10 , 11 ) , glioblastoma ( 9 , 10 , 11 ) , glioblastoma multiforme ( 4 ) , glioma ( 4 , 9 , 10 , 11 ) , gastric cancer ( 21 ) , leukemia ( 18 , 19 , 20 , 22 , 23 ) , acute lymphocytic leukemia ( 20 ) , acute myelogenous leukemia ( 18 , 19 , 22 , 23 ) , lung cancer ( 3 , 7 , 8 , 17 ) , non-small cell lung cancer ( 5 , 7 , 17 ) , non-small cell lung adenocarcinoma ( 3 , 7 ) , non-small cell squamous cell lung carcinoma ( 3 , 7 , 8 ) , neuroblastoma ( 1 , 16 ) , rhabdomyosarcoma ( 6 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Kinases, in vitro:
PDGFRA (human) ( 26 )
Treatments:
PDGF ( 24 , 26 )

Downstream Regulation
Effects of modification on PDGFRA:
molecular association, regulation ( 26 )
Induce interaction with:
PLCG1 (human) ( 26 )

References 

1

Palacios-Moreno J, et al. (2015) Neuroblastoma Tyrosine Kinase Signaling Networks Involve FYN and LYN in Endosomes and Lipid Rafts. PLoS Comput Biol 11, e1004130
25884760   Curated Info

2

Takahashi T, et al. (2013) New findings of kinase switching in gastrointestinal stromal tumor under imatinib using phosphoproteomic analysis. Int J Cancer 133, 2737-43
23716303   Curated Info

3

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

4

Johnson H, et al. (2012) Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts. Mol Cell Proteomics 11, 1724-40
22964225   Curated Info

5

Rikova K (2012) CST Curation Set: 16140; Year: 2012; Biosample/Treatment: cell line, A549/iressa, gleevec, crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) MultiMab(TM) Rabbit mAb mix Cat#: 8954
Curated Info

6

Bai Y, et al. (2012) Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res 72, 2501-11
22461510   Curated Info

7

Rikova K (2012) CST Curation Set: 13328; Year: 2012; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

8

Moritz A, et al. (2010) Akt-RSK-S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases. Sci Signal 3, ra64
20736484   Curated Info

9

Tucker M (2009) CST Curation Set: 8070; Year: 2009; Biosample/Treatment: cell line, LN444/PDGF; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

10

Tucker M (2009) CST Curation Set: 8063; Year: 2009; Biosample/Treatment: cell line, LN444/PDGF; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

11

Tucker M (2009) CST Curation Set: 8069; Year: 2009; Biosample/Treatment: cell line, LN444/PDGF; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

12

Possemato A (2009) CST Curation Set: 7155; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

13

Possemato A (2009) CST Curation Set: 7157; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

14

Possemato A (2009) CST Curation Set: 7156; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

15

Possemato A (2009) CST Curation Set: 7154; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

16

Guo A (2009) CST Curation Set: 6125; Year: 2009; Biosample/Treatment: cell line, LAN-6/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

17

Moritz A (2009) CST Curation Set: 5956; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

18

Gu T (2006) CST Curation Set: 1877; Year: 2006; Biosample/Treatment: cell line, EOL-1/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

19

Gu T (2006) CST Curation Set: 1878; Year: 2006; Biosample/Treatment: cell line, EOL-1/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

20

Gu T (2006) CST Curation Set: 1790; Year: 2006; Biosample/Treatment: cell line, SUP-T13/untreated; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

21

Guo A (2006) CST Curation Set: 1642; Year: 2006; Biosample/Treatment: cell line, SNU-1/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

22

Goss V (2003) CST Curation Set: 110; Year: 2003; Biosample/Treatment: cell line, EOL-1/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

23

Goss V (2003) CST Curation Set: 73; Year: 2003; Biosample/Treatment: cell line, EOL-1/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

24

Ikuno Y, Leong FL, Kazlauskas A (2002) PI3K and PLCgamma play a central role in experimental PVR. Invest Ophthalmol Vis Sci 43, 483-9
11818394   Curated Info

25

Yokote K, et al. (1996) Structural determinants in the platelet-derived growth factor alpha-receptor implicated in modulation of chemotaxis. J Biol Chem 271, 5101-11
8617789   Curated Info

26

Eriksson A, et al. (1995) Demonstration of functionally different interactions between phospholipase C-gamma and the two types of platelet-derived growth factor receptors. J Biol Chem 270, 7773-81
7535778   Curated Info